NCT07799519RecruitingPhase 2
Finerenone After Catheter Ablation to Reduce Atrial Fibrillation Recurrence
Finerenone for Reducing Atrial Fibrillation Recurrence After Pulmonary Vein Isolation: A Randomized Pilot Trial With Mechanistic Assessment of Epicardial Adipose Tissue Remodeling and Brown Adipose Tissue Activation
Source: ClinicalTrials.gov · Last updated 2 Sept 2026
Brief summary (registry, in English)
Atrial fibrillation (AF) is a common heart rhythm disorder associated with stroke, heart failure, and increased mortality. Catheter ablation with pulmonary vein isolation (PVI) is an effective rhythm-control strategy, but 20-30% of patients experience AF recurrence within one year. Finerenone, a nonsteroidal mineralocorticoid receptor antagonist with anti-inflammatory, antifibrotic, and metabolic effects, was associated with a lower incidence of AF in prior large trials, and preclinical studies suggest it promotes "browning" of adipose tissue and improves epicardial adipose tissue (EAT) characteristics. This single-center, randomized, investigator-blinded pilot trial will enroll 40 patients undergoing first-time catheter ablation for AF. After successful PVI, participants will be randomized 1:1 to receive finerenone or usual care for 12 months. The primary endpoint is AF recurrence (any atrial arrhythmia episode lasting 30 seconds or longer) after a 90-day blanking period, within 12 months post-ablation. Mechanistic endpoints include EAT remodeling assessed by cardiac computed tomography and echocardiography, and circulating uncoupling protein-1 (UCP1) levels as a biomarker of adipose tissue browning. The investigators hypothesize that finerenone will lower AF recurrence after ablation, partly through modulation of EAT function.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 18 Aug 2026
- Start date
- 9 Jun 2026
- Primary completion date
- 30 Jun 2028
- Lead sponsor
- National Cheng-Kung University Hospital
- Diseases
- Atrial fibrillation
- NCT number
- NCT07799519
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 40
- From 9 Jun 2026 to the primary completion date, 30 Jun 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of prior catheter-based or surgical pulmonary vein isolation
- Known hypersensitivity to the investigational drug
- Contraindications to the investigational drug, such as concomitant use of strong CYP3A4 inducers (e.g., rifampicin, carbamazepine, phenytoin, phenobarbital)
Other illness
- Severe liver disease (Child-Pugh class C)
- Active cancer or recent chemotherapy
Lab values
- Severe renal impairment (eGFR \<25 mL/min/1.73 m2)
- Serum potassium \>5.0 mmol/L
Other
- Current use of other mineralocorticoid receptor antagonists (MRAs)
- Women who are pregnant, breastfeeding, or planning to become pregnant during the study period
Who the study is looking for
- Age 18-80 years
- Atrial fibrillation scheduled for first-time catheter ablation (pulmonary vein isolation)
- Estimated glomerular filtration rate (eGFR) \>=25 mL/min/1.73 m2
- Serum potassium \<=5.0 mmol/L
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National Cheng Kung University Hospital Coordinator of this site? Confirm its status | Tainan | Taiwan | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.